Targeting of chimeric antigen receptor T cell metabolism to improve therapeutic outcomes

Genetically engineered chimeric antigen receptor (CAR) T cells can cure patients with cancers that are refractory to standard therapeutic approaches. To date, adoptive cell therapies have been less effective against solid tumors, largely due to impaired homing and function of immune cells within the...

Descripción completa

Detalles Bibliográficos
Autores principales: Nanjireddy, Priyanka Maridhi, Olejniczak, Scott H., Buxbaum, Nataliya Prokopenko
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Immunology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10043186/
https://www.ncbi.nlm.nih.gov/pubmed/36999013
http://dx.doi.org/10.3389/fimmu.2023.1121565

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10043186/
https://www.ncbi.nlm.nih.gov/pubmed/36999013
http://dx.doi.org/10.3389/fimmu.2023.1121565

Ejemplares similares